Proteomics

Dataset Information

0

Detection of candidate ovarian cancer protein biomarkers in sera using a multiplexed targeted mass spectrometry assay

ABSTRACT: Ovarian cancer is the most lethal gynecologic malignancy in women, and high-grade serous ovarian cancer (HGSOC) is the most common subtype. Currently, no clinical test has been approved by the FDA to screen the general population for ovarian cancer. This underscores the critical need for the development of a robust methodology combined with novel technology to detect diagnostic biomarkers for HGSOC in the sera of women. Targeted mass spectrometry (MS) can be used to identify and quantify specific peptides/proteins in complex biological samples with high accuracy, sensitivity, and reproducibility. In this study, we sought to develop and conduct analytical validation of a multiplexed Tier 2 targeted MS parallel reaction monitoring (PRM) assay for the relative quantification of 23 putative ovarian cancer protein biomarkers in sera.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Serum

DISEASE(S): Malignant Neoplasm Of Ovary

SUBMITTER: Joohyun Ryu  

LAB HEAD: Stefani Thomas

PROVIDER: PXD047188 | Pride | 2024-01-26

REPOSITORIES: pride

Json Xml

Dataset's files

Source:
Action DRS
B01_R1.raw Raw
B01_R2.raw Raw
B02_R1.raw Raw
B02_R2.raw Raw
B03_R1.raw Raw
Items per page:
1 - 5 of 268
altmetric image

Publications

Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay.

Ryu Joohyun J   Boylan Kristin L M KLM   Twigg Carly A I CAI   Evans Richard R   Skubitz Amy P N APN   Thomas Stefani N SN  

Clinical proteomics 20240103 1

<h4>Background</h4>Ovarian cancer is the most lethal gynecologic malignancy in women, and high-grade serous ovarian cancer (HGSOC) is the most common subtype. Currently, no clinical test has been approved by the FDA to screen the general population for ovarian cancer. This underscores the critical need for the development of a robust methodology combined with novel technology to detect diagnostic biomarkers for HGSOC in the sera of women. Targeted mass spectrometry (MS) can be used to identify a  ...[more]

Similar Datasets

Transcriptomics microRNA profiling of serum microRNA from high grade serous ovarian carcinoma
2017-01-30 | E-MTAB-4667 | biostudies-arrayexpress
Proteomics Discovery and validation of serum glycoprotein biomarker panel for detection of high grade serous ovarian cancer
2023-10-24 | PXD032299 | Pride
Proteomics Novel Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Uncovered by Data-Independent Acquisition Mass Spectrometry
2022-08-11 | PXD033169 | Pride
Proteomics Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer
2023-10-09 | PXD036726 | Pride
Transcriptomics Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas
2024-11-19 | GSE280516 | GEO
Genomics Cell Type Specific Enrichment Of Risk Associated Regulatory Elements At Ovarian Cancer Susceptibility Loci
2015-04-22 | E-GEOD-68104 | biostudies-arrayexpress
Proteomics Peptidome profiling of ovarian cancer and non-cancer proximal fluids: ascites and blood sera
2018-04-05 | PXD009382 | Pride
Proteomics Integrative proteomic profiling of ovarian cancer cell lines reveals precursor-cell associated proteins and functional status
2017-03-30 | MSV000080814 | MassIVE
Transcriptomics Transcriptomes of ex vivo grown spontaneous p53-R270H MYC murine ovarian and uterine cancers
2024-01-23 | GSE238158 | GEO
Other RNA Immunoprecipitation(RIP)-seq of Flag-USP39 in ovarian cancer cells
2021-04-20 | GSE157401 | GEO